BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

687 related articles for article (PubMed ID: 25394854)

  • 1. Effects of VBMDMP on the reversal of cisplatin resistance in human lung cancer A549/DDP cells.
    Wang CK; Zhang Y; Zhang ZJ; Qiu QW; Cao JG; He ZM
    Oncol Rep; 2015 Jan; 33(1):372-82. PubMed ID: 25394854
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CNTN-1 Enhances Chemoresistance in Human Lung Adenocarcinoma Through Induction of Epithelial-Mesenchymal Transition by Targeting the PI3K/Akt Pathway.
    Zhang R; Sun S; Ji F; Liu C; Lin H; Xie L; Yang H; Tang W; Zhou Y; Xu J; Li P
    Cell Physiol Biochem; 2017; 43(2):465-480. PubMed ID: 28934754
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Depleted aldehyde dehydrogenase 1A1 (ALDH1A1) reverses cisplatin resistance of human lung adenocarcinoma cell A549/DDP.
    Wei Y; Wu S; Xu W; Liang Y; Li Y; Zhao W; Wu J
    Thorac Cancer; 2017 Jan; 8(1):26-32. PubMed ID: 27813328
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [The roles of holothurian glycosaminoglycan combined with cisplatin on proliferation and chemotherapeutic response in A549 human lung adenocarcinoma cell].
    Jin Q; Zhu XH; Lin CZ; Zhang H; Cao YW; Ding XQ; Lyu ZH
    Zhonghua Zhong Liu Za Zhi; 2018 Apr; 40(4):252-257. PubMed ID: 29730910
    [No Abstract]   [Full Text] [Related]  

  • 5. miR-206 regulates cisplatin resistance and EMT in human lung adenocarcinoma cells partly by targeting MET.
    Chen QY; Jiao DM; Wang J; Hu H; Tang X; Chen J; Mou H; Lu W
    Oncotarget; 2016 Apr; 7(17):24510-26. PubMed ID: 27014910
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Curcumin reverses cis-platin resistance and promotes human lung adenocarcinoma A549/DDP cell apoptosis through HIF-1α and caspase-3 mechanisms.
    Ye MX; Zhao YL; Li Y; Miao Q; Li ZK; Ren XL; Song LQ; Yin H; Zhang J
    Phytomedicine; 2012 Jun; 19(8-9):779-87. PubMed ID: 22483553
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Co-treatment with BEZ235 enhances chemosensitivity of A549/DDP cells to cisplatin via inhibition of PI3K/Akt/mTOR signaling and downregulation of ERCC1 expression.
    Xia A; Li H; Li R; Lu L; Wu X
    Oncol Rep; 2018 Oct; 40(4):2353-2362. PubMed ID: 30066933
    [TBL] [Abstract][Full Text] [Related]  

  • 8. GLIPR1 modulates the response of cisplatin-resistant human lung cancer cells to cisplatin.
    Gong X; Liu J; Zhang D; Yang D; Min Z; Wen X; Wang G; Li H; Song Y; Bai C; Li J; Zhou J
    PLoS One; 2017; 12(8):e0182410. PubMed ID: 28771580
    [TBL] [Abstract][Full Text] [Related]  

  • 9. XPC inhibition rescues cisplatin resistance via the Akt/mTOR signaling pathway in A549/DDP lung adenocarcinoma cells.
    Teng X; Fan XF; Li Q; Liu S; Wu DY; Wang SY; Shi Y; Dong M
    Oncol Rep; 2019 Mar; 41(3):1875-1882. PubMed ID: 30628719
    [TBL] [Abstract][Full Text] [Related]  

  • 10. β-elemene reverses the drug resistance of lung cancer A549/DDP cells via the mitochondrial apoptosis pathway.
    Yao CC; Tu YR; Jiang J; Ye SF; Du HX; Zhang Y
    Oncol Rep; 2014 May; 31(5):2131-8. PubMed ID: 24627125
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bisdemethoxycurcumin sensitizes cisplatin-resistant lung cancer cells to chemotherapy by inhibition of CA916798 and PI3K/AKT signaling.
    Wang HJ; Yang ZX; Dai XT; Chen YF; Yang HP; Zhou XD
    Apoptosis; 2017 Sep; 22(9):1157-1168. PubMed ID: 28677094
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reversal of cisplatin resistance by inhibiting PI3K/Akt signal pathway in human lung cancer cells.
    Zhang Y; Bao C; Mu Q; Chen J; Wang J; Mi Y; Sayari AJ; Chen Y; Guo M
    Neoplasma; 2016; 63(3):362-70. PubMed ID: 26925782
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Effects of a protein kinase C inhibitor combined with cisplatin on non-small cell lung cancer].
    Gao ZQ; Han BH; Sha HF; Shi ZY; Yang XH; Feng JX
    Zhonghua Jie He He Hu Xi Za Zhi; 2010 Apr; 33(4):284-8. PubMed ID: 20646461
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Synergistic Antitumor Effect of Amorphigenin Combined with Cisplatin in Human Lung Adenocarcinoma A549/DDP Cells].
    Zhong H; Zuo Y; Wu X; Peng Y; He H; Yang J; Guan C; Xu Z
    Zhongguo Fei Ai Za Zhi; 2016 Dec; 19(12):805-812. PubMed ID: 27978865
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effects of combined treatment with sevoflurane and cisplatin on growth and invasion of human adenocarcinoma cell line A549.
    Liang H; Wang HB; Liu HZ; Wen XJ; Zhou QL; Yang CX
    Biomed Pharmacother; 2013 Jul; 67(6):503-9. PubMed ID: 23639227
    [TBL] [Abstract][Full Text] [Related]  

  • 16. siRNA-directed clusterin silencing promotes cisplatin antitumor activity in human non-small cell lung cancer xenografts in immunodeficient mice.
    Zhang B; Liu ZM; Hao FG; Wang M
    Eur Rev Med Pharmacol Sci; 2014 Jun; 18(11):1595-601. PubMed ID: 24943969
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Newcastle disease virus induces apoptosis in cisplatin-resistant human lung adenocarcinoma A549 cells in vitro and in vivo.
    Meng S; Zhou Z; Chen F; Kong X; Liu H; Jiang K; Liu W; Hu M; Zhang X; Ding C; Wu Y
    Cancer Lett; 2012 Apr; 317(1):56-64. PubMed ID: 22095029
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A novel herbal formula induces cell cycle arrest and apoptosis in association with suppressing the PI3K/AKT pathway in human lung cancer A549 cells.
    Xiong F; Jiang M; Huang Z; Chen M; Chen K; Zhou J; Yin L; Tang Y; Wang M; Ye L; Zhan Z; Duan J; Fu H; Zhang X
    Integr Cancer Ther; 2014 Mar; 13(2):152-60. PubMed ID: 24105357
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reversal of galectin-1 gene silencing on resistance to cisplatin in human lung adenocarcinoma A549 cells.
    Zhang L; Liu X; Tang Z; Li X; Wang G
    Biomed Pharmacother; 2016 Oct; 83():265-270. PubMed ID: 27392028
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combination treatment of FTY720 and cisplatin exhibits enhanced antitumour effects on cisplatin-resistant non-small lung cancer cells.
    Li Y; Hu T; Chen T; Yang T; Ren H; Chen M
    Oncol Rep; 2018 Feb; 39(2):565-572. PubMed ID: 29207165
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 35.